Vemurafenib: all 121 studies that test it

Page 1 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.

• Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
• Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal CancerRecruitingNCT06603376Phase 2
• A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)RecruitingNCT06561360Phase 2
• Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationRecruitingNCT06440850Phase 2
• Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal CancerRecruitingNCT06008119Phase 3
• Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical StudyNot yet recruitingNCT05900219Phase 2
• DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingNCT05768178Phase 2/3
• HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K MutationRecruitingNCT05263453Phase 2
• Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)RecruitingNCT05233332Phase 2
• The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingNCT05159245Phase 2
• PLATFORM Study of Precision Medicine for Rare TumorsRecruitingNCT04423185Phase 2
• A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingNCT04302025Phase 2
• A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 MutationRecruitingNCT03781219Phase 1
• The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
• TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage CancerRecruitingNCT02693535Phase 2
• A Phase I/II Trial of Vemurafenib and Metformin to Melanoma PatientsRecruitingNCT01638676Phase 1/2
• Phase II Trial of Vemurafenib and Sorafenib in Pancreatic CancerCompletedNCT05068752Phase 2Results posted
• Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid CancersCompletedNCT04462471Phase 1Results posted
• A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System MetastasesCompletedNCT03625141Phase 2Results posted
• Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III MelanomaCompletedNCT03554083Phase 2Results posted
• A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedNCT03498521Phase 2Results posted
• Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaActive, not recruitingNCT03224767Phase 2Results posted
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03220035Phase 2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasTerminatedNCT03013491Phase 1/2Results posted
• Vemurafenib and TIL Therapy for Metastatic MelanomaCompletedNCT02354690Phase 1/2Results posted
• A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)CompletedNCT02291289Phase 2Results posted
• Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain MetastasesTerminatedNCT02230306Phase 2Results posted
• S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal CancerCompletedNCT02164916Phase 2Results posted
• My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsCompletedNCT02091141Phase 2Results posted
• A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced MelanomaTerminatedNCT02050321Phase 2Results posted
• The Effects of Treatment With Vemurafenib on the Immune System in Advanced MelanomaTerminatedNCT01942993Phase 2Results posted
• A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic MelanomaCompletedNCT01910181Phase 1Results posted
• A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF MelanomaTerminatedNCT01826448Phase 1Results posted
• Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain MetastasesCompletedNCT01781026Phase 2Results posted
• A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic MelanomaCompletedNCT01765569Phase 1Results posted
• A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)CompletedNCT01765543Phase 1Results posted
• Combined BRAF-Targeted Therapy & Immunotherapy for MelanomaTerminatedNCT01754376Phase 2Results posted
• An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib ProtocolCompletedNCT01739764Phase 4Results posted
• BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell LeukemiaCompletedNCT01711632Phase 2Results posted
• Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced MelanomaCompletedNCT01673854Phase 2Results posted
• A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant MelanomaCompletedNCT01667419Phase 3Results posted
• Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic MelanomaCompletedNCT01659151Phase 2Results posted
• Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600ETerminatedNCT01586195Phase 2Results posted
• BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 MutationsTerminatedNCT01519323Phase 1Results posted
• BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced MelanomaCompletedNCT01512251Phase 1/2Results posted
• Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K MutationTerminatedNCT01474551Phase 2Results posted
• Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)TerminatedNCT01400451Phase 1Results posted
• A Study of Vemurafenib in Metastatic Melanoma Participants With Brain MetastasesCompletedNCT01378975Phase 2Results posted
• A Study of Vemurafenib in Participants With Metastatic MelanomaCompletedNCT01307397Phase 3Results posted
• A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 MutationCompletedNCT01286753Phase 2Results posted
• A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic MelanomaCompletedNCT01271803Phase 1Results posted
• A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic MelanomaCompletedNCT01264380Phase 1Results posted
• A Study of RO5185426 in Previously Treated Melanoma Patients With Brain MetastasesCompletedNCT01253564Phase 2Results posted
• A Study of RO5185426 in Patients With Metastatic MelanomaCompletedNCT01248936Phase 2Results posted
• A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic MelanomaCompletedNCT01164891Phase 1Results posted
• A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic MelanomaCompletedNCT01107418Phase 1Results posted
• A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)CompletedNCT01006980Phase 3Results posted
• A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic MelanomaCompletedNCT01001299Phase 1Results posted
• A Study of Vemurafenib in Previously Treated Patients With Metastatic MelanomaCompletedNCT00949702Phase 2Results posted
• Safety Study of PLX4032 in Patients With Solid TumorsCompletedNCT00405587Phase 1Results posted
• SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
• Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory HistiocytosisActive, not recruitingNCT04943198Phase 2
• Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicable
• Efficacy of VIC Regimen in BRAF Mutant Metastatic Colorectal CancerCompletedNCT04790448Phase 1/2
• Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable MelanomaActive, not recruitingNCT04722575Phase 2
• The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingNCT04591431Phase 2
• CRAFT: The NCT-PMO-1602 Phase II TrialCompletedNCT04551521Phase 2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3
• Cetuximab and Vemurafenib Plus FOLFIRI for BRAF V600E Mutated Advanced Colorectal Cancer (IMPROVEMENT)Status unknownNCT03727763Phase 2
• A Combination of Vemurafenib, Cytarabine and 2-chlorodeoxyadenosine in Children With LCH and BRAF V600E MutationStatus unknownNCT03585686Phase 2
• Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain MetastasesTerminatedNCT03430947Phase 2
• A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell LeukemiaActive, not recruitingNCT03410875Phase 2
• Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2
• Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma PatientsTerminatedNCT03224208Phase 2
• A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03178552Phase 2/3
• ML29255 Neoadjuvant Vemurafenib and Cobimetinib MelanomaWithdrawnNCT03005639Phase 2
• Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab TherapyStatus unknownNCT02968303Phase 2
• Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant MelanomaCompletedNCT02902029Phase 2
• Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced MelanomaTerminatedNCT02818023Phase 1
• A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced MelanomaCompletedNCT02768207Phase 2
• XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV MelanomaActive, not recruitingNCT02721459Phase 1
• Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
• A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady StateCompletedNCT02608034Phase 1
• Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic MelanomaCompletedNCT02583516Phase 2
• Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379CompletedNCT02456701Phase 1
• Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive MalignanciesCompletedNCT02441465Phase 1
• Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant MelanomaWithdrawnNCT02427893Phase 3
• Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityCompletedNCT02314481Phase 2
• Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic AlterationsActive, not recruitingNCT02304809Phase 2
• Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VCTerminatedNCT02303951Phase 2
• Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot StudyCompletedNCT02145143Early Phase 1
• A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered VemurafenibWithdrawnNCT02115035Phase 1/2
• A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic MelanomaWithdrawnNCT02068079Phase 1
• Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb StudyTerminatedNCT02052193Phase 2
• Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node MetastasesStatus unknownNCT02036086Phase 2
• Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on VemurafenibCompletedNCT01983124Phase 2
• Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer PatientsWithdrawnNCT01974258Phase 1
• Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF MutationCompletedNCT01959633Phase 1/2

← Vemurafenib overview